Boston Scientific Corporation  

(Public, NYSE:BSX)   Watch this stock  
Find more results for bsx
17.83
May 22 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 11.10 - 18.50
Open     -
Vol / Avg. 0.00/9.86M
Mkt cap 23.90B
P/E     -
Div/yield     -
EPS -0.19
Shares 1.34B
Beta 1.10
Inst. own 92%
Jul 22, 2015
Q2 2015 Boston Scientific Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 12, 2015
Boston Scientific Corp at Bank of America Merrill Lynch Health Care Conference
May 6, 2015
Boston Scientific Corp at Deutsche Bank Health Care Conference
May 5, 2015
Boston Scientific Corp Annual Shareholders Meeting
May 1, 2015
Boston Scientific Corp Investor Day Business Review - Webcast
Apr 28, 2015
Q1 2015 Boston Scientific Corp Earnings Release
Apr 28, 2015
Q1 2015 Boston Scientific Corp Earnings Call - Webcast
Mar 15, 2015
Boston Scientific Corp to discuss the WATCHMAN Device - Webcast
Mar 10, 2015
Boston Scientific Corp at Barclays Healthcare Conference - Breakout Session - Webcast
Mar 10, 2015
Boston Scientific Corp at Barclays Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -0.06% -1.61%
Operating margin 1.36% -4.08%
EBITD margin - 22.70%
Return on average assets -0.02% -0.71%
Return on average equity -0.06% -1.83%
Employees 24,000 -
CDP Score - 46

Address

300 BOSTON SCIENTIFIC WAY
MARLBOROUGH, MA 01752-1234
United States - Map
+1-508-6834000 (Phone)
+1-508-6508923 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company operates in three segments, including Cardiovascular, Rhythm Management and MedSurg. The Company’s cardiovascular segment includes Interventional Cardiology and Peripheral Interventions. The Company’s Rhythm Management segment includes Cardiac Rhythm Management and Electrophysiology. The Company’s Medsurg segment includes Endoscopy, Urology and Women’s Health, and Neuromodulation. The Company’s Interventional Cardiology business markets products, which are used for the treatment of atherosclerosis, a cause of coronary artery obstructive disease. Peripheral Interventions business sells products designed to treat peripheral disease, including medical devices used in percutaneous transluminal angioplasty (PTA) and peripheral vascular stenting.

Officers and directors

Peter M. Nicholas Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael F. Mahoney President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Joseph M. Fitzgerald Executive Vice President and President - Rhythm Management
Age: 51
Bio & Compensation  - Reuters
Daniel Brennan Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
Timothy A. Pratt Chief Administrative Officer, Executive Vice President, General Counsel, Secretary
Age: 65
Bio & Compensation  - Reuters
Supratim Bose Executive Vice President and President - Asia-Pacific, Middle East and Africa
Age: 62
Bio & Compensation  - Reuters
Keith D. Dawkins M.D. Global Chief Medical Officer, Executive Vice President
Age: 64
Bio & Compensation  - Reuters
Michael P. Phalen Executive Vice President and President - MedSurg
Age: 55
Bio & Compensation  - Reuters
Wendy Carruthers Senior Vice President - Human Resources
Age: 46
Bio & Compensation  - Reuters
Kevin J. Ballinger Senior Vice President and President, Interventional Cardiology
Age: 42
Bio & Compensation  - Reuters